文献速递治疗药物监测与药物基因组学

药物基因组学从发现到功能与机制:以乳腺癌为例

Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study.
PubMed 文献 · Clin Pharmacol Ther · 2017-12-01

本文综述药物基因组学研究策略从候选基因时代向全基因组关联研究(GWAS)及功能机制探索的演变,并以乳腺癌内分泌治疗的胚系药物基因组学研究为例,说明这些策略正广泛应用于药物反应表型的组学研究。

要点

  • 药物基因组学研究已从候选基因策略转向GWAS及功能机制探索。
  • 乳腺癌内分泌治疗的胚系药物基因组学研究可示例广泛适用的研究策略。
  • 组学技术带来新机遇的同时也伴随显著挑战。

核心结论

  • 药物基因组学处于定义、利用和应对后基因组时代组学机遇与挑战的前沿。

研究设计与样本

  • 本文为概述性综述,描述胚系药物基因组学研究策略的演变。

主要发现

  • 研究策略从候选基因时代演进至不依赖假设的全基因组关联研究(GWAS)。
  • GWAS信号需结合功能与机制研究进行后续探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biomedical research is undergoing rapid change, with the development of a series of analytical omics techniques that are capable of generating Biomedical Big Data. These developments provide an unprecedented opportunity to gain novel insight into disease pathophysiology and mechanisms of drug action and response-but they also present significant challenges. Pharmacogenomics is a discipline within Clinical Pharmacology that has been at the forefront in defining, taking advantage of, and dealing with the opportunities and challenges of this aspect of the Post-Genome Project world. This overview will describe the evolution of germline pharmacogenomic research strategies as we have moved from an era of candidate genes to agnostic genome-wide association studies (GWAS) coupled with the functional and mechanistic pursuit of GWAS signals. Germline pharmacogenomic studies of breast cancer endocrine therapy will be used to illustrate research strategies that are being applied broadly to omics studies of drug response phenotypes.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang L, Ingle J, Weinshilboum R, et al. Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clin Pharmacol Ther. 2017. PMID: 29052219. doi:10.1002/cpt.915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。